Combination therapy for the treatment of leukemia

Share This Post

Venetoclax (Venclexta) and rituximab (Rituxan) are used in combination with relapsed refractory chronic lymphocytic leukemia ( CLL ), resulting in a high rate of undetectable minimal residual disease ( uMRD ), which is associated with prolonged progression-free survival ( PFS ).

Venetoclax and rituximab-treated patients had almost 5 times the uMRD status as combined with phenytoin and rituximab , and the proportion of patients who maintained this status at 24 months was higher in the venetoclax / rituximab group the 20 or more times. Compared with MRD- positive status, uMRD was associated with a 62 % reduction in risk of disease progression or death .

The MRD status has been proven to predict PFS in CLL patients treated with chemoimmunotherapy , but the predictive value of MRD for new drugs remains uncertain. Data from the random MURANO trial provides an opportunity to examine the predictive value of MRD and CLL without chemotherapy.

MURANO is a phase III randomized trial evaluating the efficacy of rituximab combined with venetoclax versus bendamustine in 389 patients with relapsed / refractory CLL . The patient received 2 years of venetoclax and the first 6 months of rituximab, or 6 months of bendamustine plus rituximab for 6 months.

Preliminary analysis showed that compared with rituximab and bendamustine, the risk of disease progression or death was 84% at 3 years of treatment with venetoclax and rituximab.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy